Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts. (2nd July 2020)

• Record Type: Journal Article
• Authors: Maimaitiyiming, Yasen; Zhu, Hong-Hu; Yang, Chang; Naranmandura, Hua
• Is Part Of: Drug metabolism reviews. Volume 52:Number 3(2020)
• Page Start: 425
• Page End: 437
• Publication Date: 2020-07-02
• Subjects: Arsenic (+3 oxidation state) methyltransferase -- acute promyelocytic leukemia -- arsenic trioxide -- PML/RARα -- monomethylarsonous acid -- dimethylarsinous acid -- reactive oxygen species; Drugs -- Metabolism -- Periodicals; Pharmacokinetics -- Periodicals; Pharmaceutical Preparations -- metabolism -- Periodicals; 615
• DOI: 10.1080/03602532.2020.1791173
• Languages: English
• ISSNs: 0360-2532

Abstract

Abstract: Arsenic trioxide (ATO) is one of the most effective drugs for treatment of acute promyelocytic leukemia (APL). It could specifically target the PML/RARα fusion oncoprotein stability and induces APL cell differentiation as well as apoptosis. Although many studies have been conducted to document the anticancer effects and mechanism of ATO, there is little information about the association between biotransformation of ATO to active arsenic metabolites and APL therapy. Generally, ATO can be rapidly converted into trivalent methylated metabolites by arsenic (+3 oxidation state) methyltransferase (AS3MT) mostly in liver and redistributed to bloodstream of APL patients who receiving ATO treatment, thereby leading to a balance between cytotoxicity and differentiation, which is proposed to be the key event in successful treatment of APL. In this review, we comprehensively discussed possible roles of AS3MT and methylated arsenic metabolites in APL therapy, so as to reveal the association between individual differences of AS3MT expression and activity with the therapeutic efficacy of ATO in APL patients.